Antipsychotic Discontinuation in High-risk Subjects

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01758887

Enrollment

Registered

2013-01-01

Start date

2012-12-31

Completion date

2016-09-30

Last updated

2016-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

* Would be there any difference in dopamine synthesis between remitted clinical high risk subjects for psychosis and healthy control? * What would happen to dopamine synthesis after antipsychotic discontinuation in clinical high risk subjects for psychosis? * What about the dopamine synthesis in recurred clinical high risk subjects for psychosis after the discontinuation?

Detailed description

After the antipsychotic medication discontinuation, we are going to assess the changes of the biological markers

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

16 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Diagnosed as a clinical High Risk * Treated with antipsychotic drugs * PSP1-5 (from SIPS criteria) \<3 (severity index)for more than 6 months * Had not experienced a symptomatic relapse in the 6 months

Exclusion criteria

* Significant abnormality in laboratory tests * History of head trauma

Design outcomes

Primary

Measure	Time frame	Description
Presynaptic dopamine synthesis in the striatum	baseline	measured with \[18F\]DOPA positron emission tomography

Countries

South Korea

Outcome results